Dissolution Media Selection: Start at pH 1.2, Add Only What You Need

Hand-drawn dissolution lab title card

For a first-pass dissolution screen, start with 0.1 N HCl (pH 1.2) to represent the gastric stage, a pH 6.8 phosphate buffer for the intestinal stage, and one mid-range or surfactant-containing medium if your API’s solubility or log D suggests you will need it. The deciding factor is almost always the interplay of pKa, log D and intrinsic solubility: ionizable, low-solubility compounds usually need surfactant or biorelevant media sooner than neutral, highly soluble ones. Whatever you choose, be ready to justify it against USP and FDA expectations.

TL;DR:
Regulatory methods generally profile media across pH 1.2 to 6.8, require 37 ± 0.5°C and qualified apparatus, and discourage purified water because its properties drift.
For compounds with log D above roughly 3, aqueous buffers may show little discrimination; test FaSSIF when bile salts could reveal formulation differences.
Before profiling, confirm sink capacity by calculation and measurement; the medium should dissolve at least three times the drug amount needed for complete release.
For enteric coated products, use 0.1 N HCl for two hours, then switch to pH 6.8 buffer; add enzymes only for documented pellicle concerns.
If sink remains unreachable with the lowest effective surfactant level, choose Apparatus 4 rather than a high concentration that could mask formulation differences.

7ohyeaSource Research-Grade 7OH Materials7OH Canada supplies research-grade 7-hydroxymitragynine tablets and powders for analytical purposes, with customizable dosage options and domestic sourcing from British Columbia.

Visit 7OH Canada

How compendia and regulators shape acceptable media
Decision rules: pKa, solubility, log D and BCS-guided choices
Ready recipes and when to use them
Stepwise method development: apparatus, agitation, sink and suitability
Worked examples applying the rules to common development cases
Author Deek’s practical checklist and lab notes
A short view on where media selection is heading
Choosing research-grade materials for your dissolution work
FAQ
Sources

How compendia and regulators shape acceptable media

Compendial and regulatory guidance does not dictate a single medium for every drug, but it sets the boundaries you work within. The USP general chapters on dissolution and apparatus suitability specify apparatus suitability testing, temperature control at 37 ± 0.5°C, and preferred medium volumes, typically 500, 900 or 1,000 mL depending on the apparatus and dosage form. These chapters also discourage routine use of plain purified water as a dissolution medium, since its pH and surface tension drift batch to batch, which undermines the reproducibility a validated method depends on.

The FDA’s compiled resources on in-vitro dissolution testing for immediate-release solid oral dosage forms reinforce a similar philosophy: the agency’s guidance describes a typical pH range for test media and notes that purified water’s variability makes buffered systems the more defensible default. Where surfactants are necessary for poorly soluble drugs, the same guidance calls for the lowest concentration that achieves the intended effect, backed by data rather than convention.

The FDA’s broader guidance on dissolution testing and development adds the expectation that profiles are generated across several media, generally spanning pH 1.2 to 6.8, with surfactant addition and apparatus variation used as needed to establish discriminatory power before specifications are finalized.

In practice, this translates into a few routine habits worth building into every protocol:

Run an acid stage (pH 1.2) followed by a buffer stage for enteric-coated or delayed-release products, rather than testing only one pH.
Use enzymes such as pepsin or pancreatin only when a specific, documented issue (like capsule pellicle formation) justifies it.
Record the scientific rationale, pKa, log D, solubility and sink calculations, as part of the method file, since reviewers weigh that reasoning as heavily as the raw dissolution data.
Treat apparatus suitability testing and deaeration as standard steps, not optional extras, before generating any profile intended for a regulatory submission.

None of this amounts to a fixed recipe book. It is a set of guardrails that tells you where you have latitude (which specific buffer, which surfactant, which concentration) and where you do not (temperature control, apparatus qualification, documentation of rationale).

Decision rules: pKa, solubility, log D and BCS-guided choices

The fastest way to choose a sensible starting medium is to let the molecule’s own chemistry do the work. Three numbers, pKa, intrinsic solubility and log D, cover most of the decision.

Start with pKa. If your compound is a weak base, it will be most soluble at low pH and least soluble near neutral pH, so your worst-case medium is typically the intestinal buffer, not the gastric one. A weak acid behaves the opposite way: solubility drops in the acid stage and rises as pH increases. For either case, the worst-case pH is the one furthest from the compound’s point of maximum ionization, and that is the medium most likely to expose formulation differences.

Log D gives you a second filter. As a rule of thumb, once log D climbs above roughly 3, simple aqueous buffers often stop telling you much, because the drug barely dissolves regardless of pH. That is the point to bring in bile-salt-containing biorelevant media such as FaSSIF, since bile salts and phospholipids can materially shift solubility and dissolution rate for lipophilic compounds, more closely reflecting what happens after a meal or in fasted intestinal fluid.

Before committing to a full profiling campaign, a few bench checks save time:

Run a single-point equilibrium solubility measurement in each candidate medium to flag where sink conditions will be hardest to achieve.
Calculate sink conditions directly: the medium volume should hold at least three times the amount of drug needed for complete dissolution, ideally more.
Check for filter adsorption by comparing early and late filtrate concentrations; discard the first few millilitres if adsorption is evident.
Confirm the formulation wets properly in the chosen medium rather than floating or clumping, since poor wetting can masquerade as poor solubility.

Buffer strength matters more than it is often given credit for. A buffer with too little capacity will drift in pH as the drug dissolves and releases or consumes protons, which distorts the profile in a way that has nothing to do with the formulation. Common-ion effects are a related trap: if your buffer salt shares an ion with the drug’s conjugate acid or base, you can suppress solubility artificially and produce a profile that underestimates real performance.

Pro Tip:Before running a full six-vessel profile, dissolve a single tablet in your candidate medium and check visually at 15 and 30 minutes; if nothing has changed, you likely have a sink or wetting problem, not a formulation problem.

Structured solubility work in bioequivalent fasted intestinal media suggests that a small, well-chosen set of media, often as few as three, can capture most of the solubility range relevant to development, with the lowest-solubility medium standing in as a practical worst case when resources are tight.

Ready recipes and when to use them

Once the decision rules point you toward a category of medium, the next question is which specific recipe to prepare. A handful of starting points cover most development scenarios.

Medium	Typical pH / composition	When to use it
0.1 N hydrochloric acid	pH ≈ 1.2	Gastric stage, immediate-release and acid-stage testing of enteric products
Phosphate buffer	pH 6.8	Intestinal stage, the most common comparator for weak bases and many BCS I/III drugs
Acetate or citrate buffer	mid-range pH	Discriminating media for compounds with pH-dependent solubility between gastric and intestinal extremes
FaSSIF	Bile salts, lecithin, pH near 6.8	Fasted intestinal simulation for BCS II/IV compounds where buffers alone lack discriminatory power
FeSSIF	Higher bile salt and lipid content, pH ~5.0	Fed-state intestinal simulation when food effect is a concern
FaSSGF	Pepsin, low pH, low bile salt	Fasted gastric simulation, mainly for compounds sensitive to gastric enzyme activity

Compendial buffers remain the right starting point for most compounds: they are cheap, reproducible and well understood, and regulators expect to see them used before anything more elaborate. Preparation notes are straightforward, but precision matters: verify pH after full equilibration at 37°C rather than at room temperature, since buffer pH can shift measurably with temperature.

When a compendial buffer fails to discriminate, usually because the drug barely dissolves regardless of pH, surfactants are the next lever. Sodium lauryl sulphate (SLS) and polysorbates are the most common choices, and the guiding principle is the lowest concentration that achieves sink conditions, often just above the surfactant’s critical micelle concentration. Matching surfactant charge to the drug is not optional: an anionic surfactant like SLS can interact unpredictably with a cationic drug, producing complexation rather than clean solubilization, so a quick compatibility check before committing to a concentration is worth the extra hour.

Biorelevant media, FaSSIF, FeSSIF and FaSSGF, earn their place when simple buffers and surfactant systems still fail to separate formulations that are known to behave differently in vivo. These media incorporate bile salts and lipids that mimic the fasted or fed intestinal environment, and selection among FaSSIF variants often comes down to how closely a given recipe’s bile component ratios match aspirated human intestinal fluid for your therapeutic area.

A few practical caveats apply before adopting biorelevant media as routine tools:

Biorelevant components (bile salts, lecithin) are more expensive and less stable than simple buffers, often requiring same-day or short-shelf-life preparation.
Batch-to-batch variability in commercial bile salt and lecithin sources can introduce noise that complicates method validation.
Reserve biorelevant media for BCS II and IV compounds, or cases where simpler media have already been shown not to discriminate.

For formulation teams working through excipient-driven dissolution changes, our tablet formulation basics guide covers how coatings and fillers interact with the media choices described here.

Stepwise method development: apparatus, agitation, sink and suitability

A defendable dissolution method is built in a specific order, not assembled piecemeal. Working through the steps in sequence avoids the common trap of optimizing agitation speed before confirming the medium even achieves sink.

Choose the apparatus to match the dosage form. Paddle (Apparatus 2) covers most tablets and capsules; basket (Apparatus 1) suits capsules or formulations that float; Apparatus 3 (reciprocating cylinder) allows a clean medium change mid-run, which is useful for enteric or multi-stage testing; Apparatus 4 (flow-through) is the better option when sink cannot be achieved in a fixed-volume vessel, as is common for very poorly soluble compounds.
Set a starting agitation speed and plan to justify it experimentally. Higher speeds tend to reduce the method’s ability to discriminate between formulations, while speeds that are too low increase variability between vessels, so starting points of 50 rpm for basket or 50 to 75 rpm for paddle are common, refined with real data rather than assumed.
Select volume based on a sink calculation, then verify it experimentally. Standard volumes of 500, 900 or 1,000 mL are typical, but the right choice depends on dose strength and solubility in the chosen medium; confirm sink by sampling at a time point past expected full release and checking that measured concentration stays well below saturation.
Choose a filter and confirm it does not adsorb the API. Run a discard-volume check: filter several millilitres, discard it, then collect the sample used for analysis.
Run apparatus suitability testing and confirm deaeration before any profiling campaign. Dissolved gases in the medium can cause bubbles on tablets or vessel walls, distorting hydrodynamics in ways that have nothing to do with the formulation.
Control temperature tightly at 37 ± 0.5°C, since even small deviations shift solubility and, for some drugs, enzyme activity.
Decide on enzyme use case by case. Pepsin or pancreatin additions are justified mainly when gelatin capsule pellicle formation is suspected, and any inclusion should be documented with the specific observation that prompted it.
Demonstrate discrimination deliberately. Prepare two formulations with a known, purposeful difference (a coating thickness change, a particle size shift) and confirm the method separates them using an f2 similarity calculation or an equivalent statistical comparison.

Pro Tip:If two formulations you know to be different produce overlapping profiles, the problem is almost always the medium, not the formulation; move to a more discriminatory medium before changing anything else.

Worked examples applying the rules to common development cases

A BCS II lipophilic compound with log D above 3 and poor aqueous solubility typically starts in pH 6.8 phosphate buffer, which often shows flat, near-zero dissolution regardless of formulation differences. The logical next step is FaSSIF, since bile salts can reveal differences in particle size or crystal form that a simple buffer cannot detect, and a parallel bile-salt titration can confirm whether solubility is truly bile-dependent before committing to the more expensive medium for routine use.

An enteric-coated product calls for a two-stage approach by design: two hours in 0.1 N HCl to confirm the coating resists the acid stage, followed by a switch to pH 6.8 buffer to measure release in the intended absorption window. Pepsin is added to the acid stage only if the product is a gelatin capsule suspected of pellicle formation after storage, and pancreatin may be added to the buffer stage for the same reason; neither is a default step.

A very poorly soluble compound that fails to achieve sink even in a 900 mL vessel needs the sink calculation redone with surfactant included before any profiling begins. A quick screen across two or three SLS concentrations, each checked against the lowest-effective-concentration principle, usually identifies the point where sink is achieved without over-solubilizing the drug and masking real formulation differences. Where sink remains unreachable even with surfactant, Apparatus 4’s continuous flow becomes the more defensible choice than forcing an artificially high surfactant load.

Across all three cases, the pattern holds: start simple, escalate only when the simple medium fails to discriminate, and document the failure that justified each step up.

Worked examples applying the rules to common development cases — overview diagram

Author Deek’s practical checklist and lab notes

Keep a running record for every method: solubility results per medium, sink calculations with the assumptions shown, and any surfactant compatibility checks against the API’s charge. Note filter discard volumes and any pellicle testing with pepsin or pancreatin, since reviewers ask about both. When writing the justification section of a report, lead with the physicochemical rationale (pKa, log D, solubility) rather than the final medium choice; that order mirrors how a reviewer will read it. Our solubility data documentation shows one practical way to structure these records.

A short view on where media selection is heading

Biorelevant media and PBPK-linked dissolution testing are gaining ground, but they add cost, preparation time and batch variability that a routine QC method rarely needs. Mini-paddle and low-volume apparatus configurations are appealing for their closer match to physiological volumes, yet they still require the same sink and discrimination justification as any standard method. The practical stance we’d recommend: resist the pull toward complexity by default, and reach for a biorelevant or miniaturized method only once a simpler medium has demonstrably failed to tell your formulations apart.

— Deek

Choosing research-grade materials for your dissolution work

Dissolution method development depends on having reliable, well-characterized starting material, since variability in the API itself can masquerade as a medium or formulation problem. We supply research-grade 7-hydroxymitragynine and related alkaloid tablets and powders with batch-specific certificates of analysis so the solubility and sink calculations in your method file rest on documented purity rather than assumption. Dosage options let you scale bench-level solubility and sink checks to match your target vessel volume without reformulating from scratch. For teams running the pellicle and capsule-stage checks described above, our tablet friability testing guide pairs well with dissolution protocol documentation. Browse our research-grade tablets and powders to find the dosage and format that fits your next method development run.

FAQ

What is a capsule dissolution test?

A capsule dissolution test measures how quickly the active ingredient releases from a capsule shell and dissolves in a specified medium under controlled temperature and agitation. It typically uses USP Apparatus 1 (basket) or Apparatus 2 (paddle), since capsules can float or disintegrate unevenly, and testing often includes checks for shell pellicle formation that can slow release over time.

Why 900 mL in dissolution?

A volume of 900 mL is a common choice because it provides enough liquid to maintain sink conditions, keeping dissolved drug concentration well below saturation, for many standard dose strengths. The exact volume (500, 900 or 1,000 mL) is selected based on a sink calculation specific to the dose and the drug’s solubility in the chosen medium, not applied as a fixed rule.

What are the methods of dissolution?

The main compendial apparatus types are basket (Apparatus 1), paddle (Apparatus 2), reciprocating cylinder (Apparatus 3) and flow-through cell (Apparatus 4), each suited to different dosage forms and solubility challenges. Apparatus 3 and 4 are particularly useful when a medium change mid-test or continuous flow is needed to maintain sink for poorly soluble compounds.

What is discriminative dissolution media?

Discriminative dissolution media are chosen specifically because they can detect meaningful differences between formulations, such as changes in particle size, coating or manufacturing process, rather than producing flat, indistinguishable profiles. A medium is confirmed as discriminatory by testing two formulations with a known, deliberate difference and verifying the method separates their profiles using a similarity calculation such as f2.

Dissolution Media Selection: Start at pH 1.2, Add Only What You Need